Outcome Measures in Psoriatic Arthritis

Rheumatic Disease Clinics of North America

Volumn 41, Issue 4, 2015, Pages 699-710

  Coates, Laura ^a,b  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Composite measures; Disease activity; Function; Impact of disease; Outcome measures; Psoriatic arthritis; Quality of life

Indexed keywords

C REACTIVE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; PLACEBO; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT;

ANKYLOSING SPONDYLITIS DISEASE ACTIVITY SCORE; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; DACTYLITIS; DAS28; DISEASE ACTIVITY; DISEASE SEVERITY; ENTHESITIS; FATIGUE; FUNCTIONAL ASSESSMENT; GROUP FOR RESEARCH AND ASSESSMENT OF PSORIASIS AND PSORIATIC ARTHRITIS COMPOSITE EXERCISE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; LEEDS DACTYLITIS INDEX; LEEDS ENTHESITIS INDEX; MUSCULOSKELETAL DISEASE ASSESSMENT; NAIL PSORIASIS; OUTCOME ASSESSMENT; POLYARTHRITIS; PRIORITY JOURNAL; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; PSORIATIC ARTHRITIS; PSORIATIC ARTHRITIS DISEASE ACTIVITY SCORE; QUALITY OF LIFE ASSESSMENT; REVIEW; SPONDYLOARTHRITIS RESEARCH CONSORTIUM OF CANADA ENTHESITIS INDEX; VISUAL ANALOG SCALE; ARTHRITIS, PSORIATIC; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX;

ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX;

EID: 84945440969     PISSN: 0889857X     EISSN: 15583163     Source Type: Journal    
DOI: 10.1016/j.rdc.2015.07.009     Document Type: Review

References (53)

1. Gladman D.D., Mease P.J., Strand V., et al. Consensus on a core set of domains for psoriatic arthritis. J Rheumatol 2007, 34(5):1167-1170.
2. Coates L.C., FitzGerald O., Gladman D.D., et al. Reduced joint counts misclassify patients with oligoarticular psoriatic arthritis and miss significant numbers of patients with active disease. Arthritis Rheum 2013, 65(6):1504-1509.
3. Clegg D.O., Reda D.J., Mejias E., et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996, 39(12):2013-2020.
4. Jones G., Crotty M., Brooks P. Interventions for psoriatic arthritis. Cochrane Database Syst Rev 2000, (3). CD000212.
5. Fransen J., Antoni C., Mease P.J., et al. Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors. Ann Rheum Dis 2006, 65(10):1373-1378.
6. Schoels M., Aletaha D., Funovits J., et al. Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis. Ann Rheum Dis 2010, 69(8):1441-1447.
7. Wallace A.B. The exposure treatment of burns. Lancet 1951, 1(6653):501-504.
8. Fredriksson T., Pettersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 1978, 157(4):238-244.
9. Rich P., Scher R.K. Nail psoriasis severity index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol 2003, 49(2):206-212. [see comment].
10. Mander M., Simpson J.M., McLellan A., et al. Studies with an enthesis index as a method of clinical assessment in ankylosing spondylitis. Ann Rheum Dis 1987, 46(3):197-202.
11. Healy P.J., Helliwell P.S. Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis. Arthritis Rheum 2008, 59(5):686-691.
12. Maksymowych W.P., Mallon C., Morrow S., et al. Development and validation of the Spondyloarthritis Research Consortium of Canada (SPARCC) enthesitis index. Ann Rheum Dis 2009, 68(6):948-953.
13. Gladman D.D., Inman R.D., Cook R.J., et al. International spondyloarthritis interobserver reliability exercise-the INSPIRE study: II. Assessment of peripheral joints, enthesitis, and dactylitis. J Rheumatol 2007, 34(8):1740-1745.
14. Salvarani C., Cantini F., Olivieri I., et al. Efficacy of infliximab in resistant psoriatic arthritis. Arthritis Rheum 2003, 49(4):541-545.
15. Kaltwasser J.P., Nash P., Gladman D., et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 2004, 50(6):1939-1950.
16. Antoni C., Krueger G.G., de Vlam K., et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005, 64(8):1150-1157.
17. Healy P.J., Helliwell P.S. Measuring dactylitis in clinical trials: which is the best instrument to use?. J Rheumatol 2007, 34(6):1302-1306.
18. Garrett S., Jenkinson T., Kennedy L.G., et al. A new approach to defining disease status in ankylosing spondylitis: the Bath ankylosing spondylitis disease activity index. J Rheumatol 1994, 21(12):2286-2291.
19. Taylor W.J., Harrison A.A. Could the Bath ankylosing spondylitis disease activity index (BASDAI) be a valid measure of disease activity in patients with psoriatic arthritis?. Arthritis Rheum 2004, 51(3):311-315.
20. Fernandez-Sueiro J.L., Willisch A., Pertega-Diaz S., et al. Validity of the Bath ankylosing spondylitis disease activity index for the evaluation of disease activity in axial psoriatic arthritis. Arthritis Care Res (Hoboken) 2010, 62(1):78-85.
21. Lukas C., Landewe R., Sieper J., et al. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 2009, 68(1):18-24.
22. Machado P., Landewe R., Lie E., et al. Ankylosing spondylitis disease activity score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis 2011, 70(1):47-53.
23. Eder L., Chandran V., Shen H., et al. Is ASDAS better than BASDAI as a measure of disease activity in axial psoriatic arthritis?. Ann Rheum Dis 2010, 69(12):2160-2164.
24. Kilic G., Kilic E., Nas K., et al. Comparison of ASDAS and BASDAI as a measure of disease activity in axial psoriatic arthritis. Clin Rheumatol 2015, 34(3):515-521.
25. Calin A., Garrett S., Whitelock H., et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath ankylosing spondylitis functional index. J Rheumatol 1994, 21(12):2281-2285.
26. Leung Y.Y., Tam L.S., Kun E.W., et al. Comparison of 4 functional indexes in psoriatic arthritis with axial or peripheral disease subgroups using Rasch analyses. J Rheumatol 2008, 35(8):1613-1621.
27. Fries J.F., Spitz P., Kraines R.G., et al. Measurement of patient outcome in arthritis. Arthritis Rheum 1980, 23(2):137-145.
28. Blackmore M.G., Gladman D.D., Husted J., et al. Measuring health status in psoriatic arthritis: the Health Assessment Questionnaire and its modification. J Rheumatol 1995, 22(5):886-893.
29. Mease P.J., Woolley J.M., Bitman B., et al. Minimally important difference of Health Assessment Questionnaire in psoriatic arthritis: relating thresholds of improvement in functional ability to patient-rated importance and satisfaction. J Rheumatol 2011, 38(11):2461-2465.
30. Ware J.E., Sherbourne C.D. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992, 30(6):473-483.
31. EuroQol Group EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 1990, 16(3):199-208.
32. Husted J.A., Gladman D.D., Farewell V.T., et al. Validating the SF-36 health survey questionnaire in patients with psoriatic arthritis. J Rheumatol 1997, 24(3):511-517.
33. Mease P.J. Measures of psoriatic arthritis: tender and swollen joint assessment, psoriasis area and severity index (PASI), nail psoriasis severity index (NAPSI), modified nail psoriasis severity index (mNAPSI), Mander/Newcastle enthesitis index (MEI), Leeds enthesitis index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht ankylosing spondylitis enthesis score (MASES), Leeds dactylitis index (LDI), patient global for psoriatic arthritis, dermatology life quality index (DLQI), psoriatic arthritis quality of life (PsAQOL), functional assessment of chronic illness therapy-fatigue (FACIT-F), psoriatic arthritis response criteria (PsARC), psoriatic arthritis joint activity index (PsAJAI), disease activity in psoriatic arthritis (DAPSA), and composite psoriatic disease activity index (CPDAI). Arthritis Care Res (Hoboken) 2011, 63(Suppl 11):S64-S85.
34. McKenna S.P., Doward L.C., Whalley D., et al. Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis. Ann Rheum Dis 2004, 63(2):162-169.
35. Healy P.J., Helliwell P.S. Psoriatic arthritis quality of life instrument: an assessment of sensitivity and response to change. J Rheumatol 2008, 35(7):1359-1361.
36. Finlay A.Y., Khan G.K. Dermatology life quality index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol 1994, 19(3):210-216.
37. Bykerk V.P., Lie E., Bartlett S.J., et al. Establishing a core domain set to measure rheumatoid arthritis flares: report of the OMERACT 11 RA flare Workshop. J Rheumatol 2014, 41(4):799-809.
38. Schentag C., Cichon J., MacKinnon A., et al. Validation and normative data for the 0-10 point scale version of the fatigue severity scale (FSS). Arthritis Rheum 2000, 2000(43 Suppl):S177.
39. Schentag C., Gladman D. Changes in fatigue in psoriatic arthritis: disease activity of fibromyalgia. Arthritis Rheum 2002, 46(Suppl):S177.
40. Mease P.J., Gladman D.D., Ritchlin C.T., et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005, 52(10):3279-3289.
41. Chandran V., Bhella S., Schentag C., et al. Functional assessment of chronic illness therapy-fatigue scale is valid in patients with psoriatic arthritis. Ann Rheum Dis 2007, 66(7):936-939.
42. Gossec L., de Wit M., Kiltz U., et al. A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. Ann Rheum Dis 2014, 73(6):1012-1019.
43. Cauli A., Gladman D., Mathieu A., et al. Patient and physician perception of disease in psoriatic arthritis (PsA). A multicentre GRAPPA and OMERACT study. Arthritis Rheum 2007, 56(9S):610. [abstract].
44. Helliwell P.S., Fitzgerald O., Fransen J., et al. The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis 2013, 72(6):986-991. (online first 17/07/2012).
45. Coates L.C., Fransen J., Helliwell P.S. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis 2010, 69(1):48-53.
46. Coates L.C., Schentag C.T., Lee K., et al. Frequency and predictors of minimal disease activity in an observational psoriatic arthritis cohort. Ann Rheum Dis 2009, 68(3):137. [abstract].
47. Coates L.C., Helliwell P.S. Validation of minimal disease activity for psoriatic arthritis using interventional trial data. Arthritis Care Res 2010, 62(2):965-969.
48. Coates L.C., Navarro-Coy N., Brown S.R., et al. The TICOPA protocol (TIght COntrol of Psoriatic Arthritis): a randomised controlled trial to compare intensive management versus standard care in early psoriatic arthritis. BMC Musculoskelet Disord 2013, 14:101.
49. Mumtaz A., Gallagher P., Kirby B., et al. Development of a preliminary composite disease activity index in psoriatic arthritis. Ann Rheum Dis 2011, 70(2):272-277.
50. Ritchlin C.T., Kavanaugh A., Gladman D.D., et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009, 68(9):1387-1394.
51. Fitzgerald O., Helliwell P., Mease P., et al. Application of composite disease activity scores in psoriatic arthritis to the PRESTA data set. Ann Rheum Dis 2011, 71(3):358-362.
52. Helliwell P.S., Kavanaugh A. Comparison of composite measures of disease activity in psoriatic arthritis using data from an interventional study with golimumab. Arthritis Care Res (Hoboken) 2014, 66(5):749-756.
53. Helliwell P.S., FitzGerald O., Fransen J. Composite disease activity and responder indices for psoriatic arthritis: a report from the GRAPPA 2013 meeting on development of cutoffs for both disease activity states and response. J Rheumatol 2014, 41(6):1212-1217.